Evidence map›Paper›PMID 34467245›Full record

ArticleCell reports. Medicine2021

Mutant HER2 needs mutant HER3 to be an effective oncogene.

Raphael Trenker, Devan Diwanji, Natalia Jura

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Raphael TrenkerCardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
Devan DiwanjiCardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
Natalia JuraCardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
University of California, San Francisco · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Structural and Functional Studies of HER ReceptorsR35GM139636 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natalia Jura · 2021 to 2026
$2.5M
NIGMS NIH HHS R35 GM139636NIGMS NIH HHS T32 GM007618
6 · The paper itself

Abstract

Hanker et al. reveal that co-occurring missense mutations in the human epidermal growth factor receptor 2 (HER2) and its catalytically inactive homolog HER3 synergize to promote oncogenic signaling by the HER2/HER3 complex.

Indexed as

Erb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3HumansOncogenesPhosphorylationERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3

Identifiers

PMID34467245
PMCPMC8385292
OpenAlexW3187505949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.